Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial

Background Treatment development that targets cognitive impairment is hampered by a lack of biomarkers that can predict treatment efficacy. Erythropoietin (EPO) improves verbal learning and memory in mood disorders, and this scales with an increase in left hippocampal volume. This study investigated whether pretreatment left hippocampal volume, interhemisphere hippocampal asymmetry or both influenced EPO treatment response with respect to verbal learning. Methods Data were available for 76 of 83 patients with mood disorders from our previous EPO trials (EPO = 37 patients; placebo = 39 patients). We performed cortical reconstruction and volumetric segmentation using FreeSurfer. We conducted multiple linear regression and logistic regression to assess the influence of left hippocampal volume and hippocampal asymmetry on EPO-related memory improvement, as reflected by change in Rey Auditory Verbal Learning Test total recall from baseline to post-treatment. We set up a corresponding exploratory general linear model in FreeSurfer to assess the influence of prefrontal cortex volume on verbal learning improvement, controlling for age, sex and total intracranial volume. Results At baseline, more rightward (left < right) hippocampal asymmetry — but not left hippocampal volume per se — was associated with greater effects of EPO versus placebo on verbal learning (p ≤ 0.05). Exploratory analysis indicated that a larger left precentral gyrus surface area was also associated with improvement of verbal learning in the EPO group compared to the placebo group (p = 0.002). Limitations This was a secondary analysis of our original EPO trials. Conclusion Rightward hippocampal asymmetry may convey a positive effect of EPO treatment efficacy on verbal learning. Clinical trial registration Clinicaltrials.gov NCT00916552

[1]  K. Miskowiak,et al.  Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review , 2019, European Neuropsychopharmacology.

[2]  Marcelo Antônio Oliveira Santos,et al.  Global hippocampal atrophy in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. , 2018, Trends in psychiatry and psychotherapy.

[3]  K. Miskowiak,et al.  Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review , 2018, Front. Psychiatry.

[4]  Ling Yue,et al.  Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese , 2018, Front. Psychiatry.

[5]  Bruce Fischl,et al.  False positive rates in surface-based anatomical analysis , 2018, NeuroImage.

[6]  R. Bucks,et al.  Hippocampal atrophy, asymmetry, and cognition in type 2 diabetes mellitus , 2017, Brain and behavior.

[7]  E. Vieta,et al.  Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives. , 2017, Journal of affective disorders.

[8]  A. Young,et al.  Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force , 2017, Bipolar disorders.

[9]  A. Meyer-Lindenberg,et al.  Hippocampal–prefrontal connectivity as a translational phenotype for schizophrenia , 2017, European Neuropsychopharmacology.

[10]  M. Vinberg,et al.  Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. , 2016, Journal of Clinical Psychiatry.

[11]  K. Miskowiak,et al.  Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field , 2016, European Neuropsychopharmacology.

[12]  Jonathan J. Evans,et al.  Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: A systematic review. , 2016, Journal of affective disorders.

[13]  M. Vinberg,et al.  Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. , 2016, Journal of affective disorders.

[14]  M. Vinberg,et al.  The effect of erythropoietin on cognition in affective disorders – Associations with baseline deficits and change in subjective cognitive complaints , 2016, European Neuropsychopharmacology.

[15]  H. Ullum,et al.  Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools. , 2016, Journal of affective disorders.

[16]  H. Siebner,et al.  Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders , 2015, Biological Psychiatry.

[17]  M. Leboyer,et al.  Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report , 2014, Acta psychiatrica Scandinavica.

[18]  P. Andersen,et al.  Starting lithium prophylaxis early v. late in bipolar disorder , 2014, British Journal of Psychiatry.

[19]  Joaquim Radua,et al.  Structural Abnormalities in Bipolar Euthymia: A Multicontrast Molecular Diffusion Imaging Study , 2014, Biological Psychiatry.

[20]  M. Vinberg,et al.  Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. , 2014, The Journal of clinical psychiatry.

[21]  J. Bukh,et al.  Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial , 2014, Neuropsychopharmacology.

[22]  T. Vos,et al.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet.

[23]  R. Lebel,et al.  Structural Changes in Hippocampal Subfields in Major Depressive Disorder: A High-Field Magnetic Resonance Imaging Study , 2013, Biological Psychiatry.

[24]  R M Peshock,et al.  MR Imaging of Hippocampal Asymmetry at 3T in a Multiethnic, Population-Based Sample: Results from the Dallas Heart Study , 2013, American Journal of Neuroradiology.

[25]  Torbjørn Elvsåshagen,et al.  Evidence for reduced dentate gyrus and fimbria volume in bipolar II disorder , 2013, Bipolar disorders.

[26]  G. MacQueen,et al.  The Hippocampus in Major Depression , 2012 .

[27]  M. Keshavan,et al.  A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia , 2011, Schizophrenia Research.

[28]  Sébastien Ourselin,et al.  Head size, age and gender adjustment in MRI studies: a necessary nuisance? , 2010, NeuroImage.

[29]  Nicholas D. Walsh,et al.  Subregional hippocampal deformations in major depressive disorder. , 2010, Journal of affective disorders.

[30]  Nicolas Cherbuin,et al.  Mild Cognitive Disorders are Associated with Different Patterns of Brain asymmetry than Normal Aging: The PATH through Life Study , 2010, Front. Psychiatry.

[31]  G. Wörtwein,et al.  Electroconvulsive stimulations prevent stress-induced morphological changes in the hippocampus , 2008, Stress.

[32]  M. Joëls,et al.  Opposite effects of glucocorticoid receptor activation on hippocampal CA1 dendritic complexity in chronically stressed and handled animals , 2008, Hippocampus.

[33]  B. Czéh,et al.  What causes the hippocampal volume decrease in depression? , 2007, European Archives of Psychiatry and Clinical Neuroscience.

[34]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[35]  F. Holsboer,et al.  Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. , 2001, The American journal of pathology.

[36]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Anders M. Dale,et al.  Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.

[38]  T. Brugha,et al.  SCAN. Schedules for Clinical Assessment in Neuropsychiatry. , 1990, Archives of general psychiatry.

[39]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[40]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[41]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[42]  G. MacQueen,et al.  Abnormal hippocampal activation in patients with extensive history of major depression: an fMRI study. , 2012, Journal of psychiatry & neuroscience : JPN.

[43]  J. Aldenhoff,et al.  Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia , 2011, Molecular Psychiatry.

[44]  G. MacQueen,et al.  A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. , 2009, Journal of psychiatry & neuroscience : JPN.

[45]  T. Johnson,et al.  Cognitive ^ behavioural therapy for severe and recurrent bipolar disorders Randomised controlled trial , 2006 .

[46]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[47]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[48]  H. Sackeim,et al.  The definition and meaning of treatment-resistant depression. , 2001, The Journal of clinical psychiatry.